Comparative Pharmacology
Head-to-head clinical analysis: PERINDOPRIL ERBUMINE versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERINDOPRIL ERBUMINE versus UNIVASC.
PERINDOPRIL ERBUMINE vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perindopril is a prodrug that is hydrolyzed to perindoprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and catecholamine release, leading to decreased blood pressure.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
2.5–10 mg orally once daily; initial dose 2.5 mg for hypertension, 4 mg for stable coronary artery disease; titrate based on response.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
The terminal elimination half-life of perindopril is 1.5–3 hours, but for the active metabolite perindoprilat it is 30–120 hours, due to slow dissociation from tissue ACE. This long half-life supports once-daily dosing for 24-hour blood pressure control.
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Perindopril is extensively metabolized to perindoprilat. Approximately 75% of an oral dose is excreted in urine (as perindoprilat and metabolites) and 25% in feces (mainly as perindoprilat). Less than 5% is excreted unchanged in urine. Biliary excretion is minimal.
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor